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Background
Increased levels of the infl  ammatory biomarker high-sensitivity C-reactive protein predict cardiovascular events. Since 
statins lower levels of high-sensitivity C-reactive protein as well as cholesterol, we hypothesized that people with 
elevated high-sensitivity C-reactive protein levels but without hyperlipidemia might benefi  t from statin treatment.
Methods
Objective: To investigate whether treatment with rosuvastatin, 20 mg daily, as compared to placebo, would decrease 
the rate of fi  rst major cardiovascular events.
Design: Randomized, double-blind, placebo-controlled, multicenter trial.
Setting: 1315 sites in 26 countries.
Subjects: 17,802 apparently healthy men and women with low-density lipoprotein (LDL) cholesterol levels of less 
than 130 mg per deciliter (3.4 mmol per liter) and high-sensitivity C-reactive protein levels of 2.0 mg per liter or higher.
Intervention: Subjects were randomly assigned to rosuvastatin, 20 mg daily, or placebo.
Outcomes: The primary outcome was the occurrence of a fi  rst major cardiovascular event, defi  ned as myocardial 
infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death from cardiovascular causes. 
Secondary endpoints included the components of the primary end point considered individually as well as death 
from any cause.
Results
The trial was stopped after a median follow-up of 1.9 years (maximum, 5.0). Rosuvastatin reduced LDL cholesterol 
levels by 50% and high-sensitivity C-reactive protein levels by 37%. The rates of the primary end point were 0.77 
and 1.36 per 100 person-years of follow-up in the rosuvastatin and placebo groups, respectively (hazard ratio for 
rosuvastatin, 0.56; 95% confi  dence interval [CI], 0.46 to 0.69; P<0.00001), with corresponding rates of 0.17 and 0.37 for 
myocardial infarction (hazard ratio, 0.46; 95% CI, 0.30 to 0.70; P=0.0002), 0.18 and 0.34 for stroke (hazard ratio, 0.52; 95% 
CI, 0.34 to 0.79; P=0.002), 0.41 and 0.77 for revascularization or unstable angina (hazard ratio, 0.53; 95% CI, 0.40 to 0.70; 
P<0.00001), 0.45 and 0.85 for the combined end point of myocardial infarction, stroke, or death from cardiovascular 
causes (hazard ratio, 0.53; 95% CI, 0.40 to 0.69; P<0.00001), and 1.00 and 1.25 for death from any cause (hazard ratio, 
0.80; 95% CI, 0.67 to 0.97; P=0.02). Consistent eff  ects were observed in all subgroups evaluated. The rosuvastatin group 
did not have a signifi  cant increase in myopathy or cancer but did have a higher incidence of physician-reported 
diabetes.
Conclusions
In this trial of apparently healthy persons without hyperlipidemia but with elevated high-sensitivity C-reactive protein 
levels, rosuvastatin signifi  cantly reduced the incidence of major cardiovascular events. (ClinicalTrials.gov number, 
NCT00239681.)
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It is well known that statins reduce the risk of myocardial 
infarction, stroke, and death from cardiovascular events 
in patients with established vascular disease and in those 
with risk factors, such as diabetes or hyperlipidemia. Yet, 
half of all myocardial infarctions and strokes occur 
among otherwise healthy men and women without 
known vascular disease or risk factors [1]. Inﬂ  ammation 
is thought to play a central role in the development and 
progression of vascular disease. In addition to their lipid-
lowering eﬀ  ects, statins have anti-inﬂ  ammatory proper-
ties, reducing levels of high-sensitivity C-reactive protein 
(hsCRP), an acute-phase protein found in the blood that 
rises in response to inﬂ   ammation. HsCRP level is a 
stronger predictor of cardiovascular events than the LDL 
cholesterol level and that it adds prognostic information 
to that conveyed by the Framingham risk score [2]. What 
is not known, however, is whether statins might also 
beneﬁ   t patients with evidence of inﬂ  ammation  but 
without vascular disease or hyperlipidemia.
Th  e  Justiﬁ  cation for the Use of Statins in Prevention: an 
Intervention Trial Evaluating Rosuvastatin (JUPITER) 
trial was designed to look at the eﬀ  ects of rosuvastatin in 
healthy patients with elevated hsCRP levels but without 
hyperlipidemia [1]. It was conducted in 1315 sites in 26 
countries and ﬁ  nancially supported by AstraZeneca, the 
makers of rosuvastatin. Between 2003 and 2006, over 
17,000 subjects were enrolled with a mean follow-up time 
of 1.9 years. As expected, treatment with rosuvastatin 
reduced LDL and hsCRP levels signiﬁ  cantly. Rosuvastatin 
reduced the primary endpoint of a ﬁ  rst  major 
cardiovascular event (absolute risk 1.6% vs. 2.8%, hazard 
ratio 0.56, p<0.00001) as well as all secondary endpoints 
with the exception of hospitalization for unstable angina. 
Th   e number needed to treat to prevent the occurrence of 
one primary endpoint in 2 years was 95, dropping to 31 
for 4 years, and 25 for 5 years of therapy. Results of the 
study were consistent across clinically important sub-
groups. Total adverse events did not diﬀ  er  between 
groups. Muscle weakness, stiﬀ   ness, or pain was fairly 
common but did not diﬀ  er between groups (16.0% vs. 
15.4%, rosuvastatin vs. placebo, p=0.34). Myopathy was 
uncommon (<0.1%) and only a single case of rhabdo-
myolysis occurred, this in a 90-year old subject with 
inﬂ   uenza, pneumonia, and trauma-induced myopathy. 
Interestingly, physician-reported diabetes was more 
frequent in the rosuvastatin group.
Th  is was a very large, well-conducted study using 
clinically meaningful endpoints which may expand the 
use of statins for primary prevention to new patient 
populations. A few limitations deserve mention. At base-
line characteristics, patients were not entirely free of risk 
prior to randomization. Patients were overweight 
(median body-mass index 28) and over 40% had features 
of the metabolic syndrome. Furthermore, 16% were 
current smokers and 11% had a family history of 
premature coronary heart disease. Even so, prevalence of 
these risk factors actually increases the generalizability of 
this study, given their frequency in Western societies. 
Th  e study did not include people with low levels of 
hsCRP and therefore does not address the use of statins 
in patients without evidence of inﬂ  ammation. However, 
as the authors note their prior work showed extremely 
low event rates and no evidence that statin therapy 
lowered vascular risk among healthy subjects with 
neither hyperlipidemia nor elevated hsCRP levels [3].
Statins, like many preventative measures, must be 
taken for years before yielding a beneﬁ   t. If guidelines 
were expanded to address C-reactive protein, it is 
estimated that an additional 6 to 8 million adults in the 
United States would have a statin indication based on 
JUPITER inclusion criteria [4]. Th   ough not without cost, 
statin therapy is this patient population would be cost-
eﬀ   ective, with a cost per quality adjusted life-year 
(QALY) of $40,457, well below the traditional cutoﬀ   of 
$50,000 per QALY [4].
Other than general medical interest, one might ask why 
this study would appeal to the intensivist. Th  e anti-
inﬂ  ammatory and anti-thrombotic properties of statins 
have prompted speculation that they may be useful in the 
treatment or prevention of severe sepsis [5], a syndrome 
characterized by dysregulation of inﬂ  ammation, coagu-
lation, and other acute phase responses. In murine 
models of sepsis, statins improve survival  [6-8]. A variety 
of observational studies in humans have examined the 
role of statins in the prevention or treatment of infection 
and sepsis, as recently reviewed [9]. Most suggest a 
clinical beneﬁ  t for statins, yet others show no beneﬁ  t, and 
one shows possible harm. Based on these ﬁ  ndings, 
several randomized trials of statins in infection are either 
planned, underway, or recently completed [10-21]. 
Unfortunately, these are small studies that are under-
powered to address mortality or other clinically meaning-
ful endpoints, with their primary endpoints focus  ing on 
inﬂ   ammatory cytokines and markers of endo  thelial 
function. In addition to their potential before or during 
severe infection, one study highlights the poten  tial for 
statins after infection. In subjects who survived an initial 
hospitalization for community-acquired pneumonia, 
circulating IL-6 concentrations at hospital discharge were 
higher among subjects who subsequently died of 
cardiovascular diseases [22], raising the possibility of 
statin use to mitigate the eﬀ  ects of ongoing subclinical 
inﬂ  ammation after hospitalization for infection.
Recommendation
Statins reduced risk of ﬁ  rst major cardiovascular event in 
healthy subjects with elevated hsCRP but without 
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cost-eﬀ  ective from a societal perspective. Even so, society 
may wish to focus on aggressive reduction of traditional 
risk factors (obesity, hypertension, diabetes) before 
broadly increasing statin use. Th   ough the results of statin 
trials in infection and severe sepsis are anxiously 
anticipated, larger studies will be needed before statins 
are routinely recommend in the management of severe 
infections.
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